Dermira (DERM) Misses Q2 EPS by 3c, reaffirms FY Guidance

Dermira (NASDAQ: DERM) reported Q2 EPS of ($0.17), $0.03 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.86 million versus the consensus estimate of $13.89 million.

Claude Maraoui, Journey Medical’s Co-Founder, President and Chief Executive Officer, said, “We continued to execute on our business plan in the second quarter, delivering $14.9 million in total net product revenue and positive Adjusted EBITDA. We are pleased with these results, particularly given our strategic decision to reduce the Company’s expense base in 2023. We believe that the business is now sufficiently right-sized to support our core dermatology franchise and effectively launch DFD-29. We’re looking forward to the DFD-29 PDUFA date and anticipate a productive second half of 2024 with additional business progress and continued financial performance. Importantly, we grew revenue 14% sequentially from the first quarter of this year as we remain on track to deliver on our 2024 financial guidance. We also strengthened our corporate team with the appointment of Joseph M. Benesch as our permanent Chief Financial Officer and the appointment of Michael C. Pearce to our Board of Directors.”

For earnings history and earnings-related data on Dermira (DERM) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat